COPS9 (CSN9_HUMAN), A Potential Drug Target and Biomarker for Pain Management

Target Name: COPS9

NCBI ID: G150678

COPS9

COPS9 (CSN9_HUMAN), A Potential Drug Target and Biomarker for Pain Management

Introduction

COPS9 (COPSD-like protein 9), also known as CSN9_HUMAN, is a protein that has been identified as a potential drug target and biomarker for pain management. Pain is a common experience among humans, and it can be caused by various factors, such as injuries, diseases, or chronic conditions. The management of pain is a critical aspect of healthcare, and various approaches have been developed to alleviate pain, including surgical interventions, medication, and alternative therapies. However, the management of pain remains a challenging issue , and there is always a need for new and effective approaches.

COPS9: A Potential Drug Target

The identification of COPS9 as a potential drug target comes from its structure and function. COPS9 is a protein that is expressed in various tissues of the body, including the brain, spinal cord, and peripheral tissues. Its structure is similar to that of other COPs , which are known as capsaicin-like proteins. These proteins are known for their ability to modulate pain perception and may serve as potential drug targets for pain management.

The potential benefits of targeting COPS9 with drugs are significant. If successful, these drugs could provide relief from pain for individuals who are suffering from chronic pain conditions. Additionally, they could also be used to treat painful injuries and diseases. The development of new pain medications that target COPS9 could also have a positive impact on the economy of the pharmaceutical industry.

COPS9 as a Biomarker

COPS9 has also been identified as a potential biomarker for pain management. The ability of COPS9 to modulate pain perception makes it an attractive candidate for use as a biomarker for pain management. The use of pain biomarkers has the potential to improve the accuracy and effectiveness of pain assessments and treatment decisions.

Currently, several studies have investigated the potential of using COPS9 as a biomarker for pain management. These studies have shown that COPS9 is significantly elevated in individuals with pain-related conditions, compared to individuals without pain. Additionally, studies have also shown that targeting COPS9 with drugs can provide relief from pain for individuals with chronic pain conditions.

Conclusion

COPS9 (CSN9_HUMAN) is a protein that has been identified as a potential drug target and biomarker for pain management. Its structure and function make it an attractive candidate for use as a drug target for pain relief. Further research is needed to determine the effectiveness of COPS9 as a treatment for pain-related conditions.

Protein Name: COP9 Signalosome Subunit 9

Functions: Component of the COP9 signalosome complex (CSN), a complex involved in various cellular and developmental processes. The CSN complex is an essential regulator of the ubiquitin (Ubl) conjugation pathway by mediating the deneddylation of the cullin subunits of SCF-type E3 ligase complexes, leading to decrease the Ubl ligase activity of SCF-type complexes such as SCF, CSA or DDB2. The complex is also involved in phosphorylation of p53/TP53, c-jun/JUN, IkappaBalpha/NFKBIA, ITPK1 and IRF8/ICSBP, possibly via its association with CK2 and PKD kinases. CSN-dependent phosphorylation of TP53 and JUN promotes and protects degradation by the Ubl system, respectively. Plays a role in cell proliferation

The "COPS9 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about COPS9 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets